MedTrace Logo

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

NCT00632970 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2018-08-29

Study results available
· View outcomes & findings →

Summary

This program is designed to study the efficacy, safety, lipid effects and tolerability of raltegravir compared to lopinavir/ritonavir, in patients with HIV-I infection who have not received prior antiretroviral therapy. All patients will receive concomitant therapy with Truvada.

Conditions

  • HIV Infections

Interventions

DRUG

Raltegravir

1, 400mg tablet twice a day, with Truvada 1 tablet once a day

DRUG

Lopinavir/Ritonavir

2 tablets twice a day, with Truvada 1 tablet once a day

DRUG

Truvada

1 tablet, once a day, with either Raltegravir (Isentress) or Lopinavir/Ritonavir(Kaletra)

Sponsors & Collaborators

  • George Washington University

    lead OTHER

Principal Investigators

  • Gary Simon, MD, PhD · George Washington University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-02-28
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00632970 on ClinicalTrials.gov